CCHR CO

Seroquel’s Toll

Controversial Pill Now Marketed for Depression

By MARTHA ROSENBERG

Even though AstraZeneca’s antipsychotic Seroquel is the fifth best-selling medication in the US according to drugs.com, exceeded only by Lipitor, Nexium, Plavix and Advair diskus, its safety, effectiveness, clinical trial and promotion records are highly checkered.

An original backer, psychiatrist Richard Borison, was sentenced to a 15-year prison sentence in 1998 for a pay-to-play Seroquel research scheme.

Its US medical director Wayne MacFadden had sexual affairs with two different women involved with Seroquel research, say published reports.

Chicago psychiatrist Michael Reinstein received $500,000 from AstraZenenca and wrote 41,000 prescriptions for Seroquel reports the Chicago Tribune and ProPublica.

Psychiatrist Charles Nemeroff who left Emory University in disgrace after a Congressional investigation for unreported pharma income, promoted Seroquel in continuing medical education courses according to the web site of psychiatrist Daniel Carlat.

Florida child psychiatrist Jorge Armenteros was chairman of the FDA committee responsible for recommending Seroquel approvals while a paid AstraZeneca speaker himself, said the Philadelphia Inquirer in 2009.

Psychiatrist Charles Schulz’ high profile pro-Seroquel presentations are suspected of being colored by his AstraZeneca income says the Minneapolis Star Tribune.

And unexplained Iraq and Afghanistan troop deaths are linked to Seroquel reported the Associated Press in August.

Originally approved for schizophrenia in 1997, Seroquel has subsequently been approved for bipolar disorder, for some groups of kids and as an add-drug for depression. This “indications creep” has mostly flown below the public’s radar. Seroquel expansion to treat children in late 2009, for example, was noted as a mere “label change” on the FDA web site. Hello?

Even without its depression indication, Seroquel is big business for AstraZeneca, earning $4.9 billion in sales in 2009. It is the drug that North Carolina’s Medicaid spends the most on: $29.4 million per year, reports the Charlotte News and Observer.

But now, as AstraZeneca rolls out its “Still Trying to Get Ahead of Your Depression” campaign, there are new questions about Seroquel’s safety and effectiveness.

According to an FDA warning letter, an AstraZeneca sales representative during an unsolicited sales call on January 3, 2008 sold Seroquel as a treatment for major depressive disorder to a physician before it was approved for MDD, an infraction which is illegal.

Once Seroquel was approved for depression (as an add-on treatment to an antidepressant for patients with major depressive disorder who not have an adequate response to antidepressant therapy), its leave-behind sheets drew another FDA warning letter.

AstraZeneca implied patients would achieve “remission” from depression with Seroquel XR (extended release) as opposed to with an antidepressant alone, says FDA — a claim not backed up by clinical experience.

Seroquel’s effect on depression has only been demonstrated in two, six-week trials FDA further said and six weeks is “not a long enough time period to adequately assess remission.” (It was approved…why?)

Also the case study of “Catherine F.” depicted in leave-behind sheets is inaccurate says FDA because it suggests Seroquel alleviates “symptoms of sadness and loss of interest when this has not been demonstrated by substantial evidence or substantial clinical experience.” (It was approved…why?)

Even AstraZeneca’s own briefing to the FDA committee in 2009 admits a “failed study” in which both Seroquel and Lexapro “failed to differentiate from placebo” which is Clinical Trial for “didn’t work.”

Nor did AstraZeneca adequately disclose Seroquel risks says FDA which include increased mortality in elderly patients with dementia-related psychosis, suicidality, neuroleptic malignant syndrome, hyperglycemia and diabetes mellitus, hyperlipidemia, weight gain and other serious side effects.

In fact, in addition to risks like cataracts, seizures and increases in blood pressure in children and adolescents, already on the Seroquel label, FDA asked AstraZeneca to add the “risk of EPS and withdrawal syndrome in neonates” a few months ago: movement disorders which can affect mothers’ babies if the mothers are taking Seroquel and stop.

But the FDA might also look at what the government’s other hand is doing. In May the Office of the Army Surgeon General’s final report on the findings of its Pain Management Task Force unabashedly hawks Seroquel for an unapproved use.

“Physicians should consider these medications for sleep disorders,” says the 163-page report,” listing Ambien and Seroquel (quetiapine) “for nightmares” even though Seroquel has never been approved for insomnia, sleep disorders or “nightmares.”

Maybe the government will send itself a warning letter.

Martha Rosenberg can be reached at: martharosenberg@sbcglobal.net

This article was re-printed with permission from Martha Rosenberg.

Study Reveals Top Ten Violence-Inducing Prescription Drugs [– Eight Are Psychiatric Drugs]

By Ethan A. Huff

(NaturalNews) The Institute for Safe Medication Practices (ISMP) recently published a study in the journal PLoS One highlighting the worst prescription drug offenders that cause patients to become violent. Among the top-ten most dangerous are the antidepressants Pristiq (desvenlafaxine), Paxil (paroxetine) and Prozac (fluoxetine).

Concerns about the extreme negative side effects of many popular antidepressant and antipsychotic drugs have been on the rise, as these drugs not only cause severe health problems to users, but also pose a significant threat to society. The ISMP report indicates that, according to the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System, many popular drugs are linked even to homicides.

Most of the drugs in the top ten most dangerous are antidepressants, but also included are an insomnia medication, an attention-deficit hyperactivity disorder (ADHD) drug, a malaria drug and an anti-smoking medication.

As reported in Time, the top ten list is as follows:

10. Desvenlafaxine (Pristiq) – An antidepressant that affects serotonin and noradrenaline. The drug is 7.9 times more likely to be associated with violence than other drugs.

9. Venlafaxine (Effexor) – An antidepressant that treats anxiety disorders. The drug is 8.3 times more likely to be associated with violence than other drugs.

8. Fluvoxamine (Luvox) – A selective serotonin reuptake inhibitor (SSRI) drug that is 8.4 times more likely to be associated with violence than other drugs.

7. Triazolam (Halcion) – A benzodiazepine drug for insomnia that is 8.7 times more likely to be associated with violence than other drugs.

6. Atomoxetine (Strattera) – An ADHD drug that is 9 times more likely to be associated with violence than other drugs.

5. Mefoquine (Lariam) – A malaria drug that is 9.5 times more likely to be associated with violence than other drugs.

4. Amphetamines – This general class of ADHD drug is 9.6 times more likely to be associated with violence than other drugs.

3. Paroxetine (Paxil) – An SSRI antidepressant drug that is 10.3 times more likely to be associated with violence than other drugs. It is also linked to severe withdrawal symptoms and birth defects.

2. Fluoxetine (Prozac) – A popular SSRI antidepressant drug that is 10.9 times more likely to be associated with violence than other drugs.

1. Varenicline (Chantix) – An anti-smoking drug that is a shocking 18 times more likely to be associated with violence than other drugs.

This article was re-printed with permission from Natural News Reader Service. You can read it here: Natural News

Note from CCHR: For an in-depth look at the link between psychiatric drugs and school shootings watch the Fox National News Exposé, Deadly Drugs

First-Person Story: Aurora Public Schools as a Feeder Line to the Psychiatric Drugging of Children

Children are continually “under the microscope” of the school psychologist

This mother’s story illustrates how psychologists and psychiatrists have turned schools from places of learning into psychiatric clinics, “diagnosing” millions of schoolchildren with ADHD and other “mental disorders” that have no valid scientific basis, then pressuring parents to drug their children. For more information, read “Child Drugging: Psychiatry Destroying Lives”. For information on the dangers of ADHD and other psychiatric drugs, click here.

My 7-year-old son attended an elementary school in the Aurora public school system last year. A couple of weeks after my son started school, he began to experience some problems in keeping up with the schoolwork.

I volunteered to help in my child’s classroom a few hours per week. I observed that the teacher was pushing ahead with the subject matter before many children had a chance to fully grasp it, and that words were being used that the children did not understand. I understood why my son was becoming inattentive and unwilling to do his schoolwork in class.

I also witnessed the extent to which a school psychologist was present in the classroom. Almost every time I spent time in that classroom, a psychologist came in and took notes while watching these kids. I realized that this monitoring of the children was constant – that they were all being “put under the microscope” to find “abnormal” behavior. I know that there were at least a few children in the classroom who were already considered to be “behavior problems.”

At the parent-teacher conferences for my son, I was surprised that two school psychologists also attended. They discussed how my child’s behavior was the problem. I told them the real cause was educational issues and that an educational approach was needed.

The teacher suggested a problem-solving team (“PST”) meeting about my son with a group of teachers who worked together to find solutions for students who needed help. At the PST meeting, a school psychologist was again in attendance. The words “hyper” and “attention” were used numerous times. The school psychologist took over the conversation. She wanted my son in one of her behavioral groups, and although “ADHD” was not mentioned outright, it was quite obvious that was what she had concluded about my child. I knew that I would be pressured to put my child on an ADHD drug next. I had already heard the classroom teacher praising another mother for putting her child on an ADHD drug.

I did not consent to my son being in this behavioral group. I had actually put a good amount of time learning about “ADHD” and was aware of the fact that there was no scientific evidence of its existence. I said I would take the matter into my own hands and work with my child on his educational needs. The school psychologist then responded that if she observed “symptoms” in a child, she was “required to report it.” I felt she was subtly threatening me. I felt that under pressure from the school psychologist, the school would continue to push for labeling my son with a mental disorder and putting him on drugs.

I removed my son from the school district, deciding instead to home-school him with the Applied Scholastics Online program. It has allowed me to assess exactly what was previously missed in my child’s education and to zero in on any areas that need extra work. Best of all, he is having a blast and is learning like a thirsty sponge!

*****

If you have experienced pressure from school personnel to have your child labeled with a mental disorder and drugged, and you want to talk about it, we want to talk to you. Email us or call 303-789-5225. All inquiries and communication will be handled in strictest confidence. We will take action.

Top 10 Wyoming Medicaid Prescribers Wrote Prescriptions Totaling $5 Million on Six Antipsychotic Drugs in 2008 and 2009

U.S. Senator Requests List in Probe of Rising Medicaid Costs

Wyoming’s top 10 Medicaid prescribers of drugs at the center of a U.S. senator’s probe into fraud, waste and abuse in the Medicaid system wrote prescriptions on six antipsychotic drugs totaling $5 million in 2008 and 2009.

The Wyoming Department of Health compiled the data in response to a request from U.S. Senator Charles Grassley of Iowa, ranking Republican on the Senate Finance Committee, which oversees Medicaid and Medicare.

In April the senator requested 2008 and 2009 data from all 50 state Medicaid agencies on the top 10 Medicaid prescribers for each of six antipsychotic and two narcotic drugs in an effort to identify “outlier” doctors who have prescribed certain drugs in much greater quantities than other doctors.

“The overutilization of prescription drugs, whether through drug abuse or outright fraud, plays a significant role in the rising cost of our health care system,” Grassley wrote.

The most glaring example, cited by Grassley in a letter to Health and Human Services Secretary Kathleen Sebelius, was a Florida doctor who wrote 96,685 prescriptions for psychiatric drugs in 21 months, with the cost billed to the state’s Medicaid program.

Because Wyoming’s top Medicaid antipsychotic prescribers are not identified by name in the Department of Health data, it is not possible to track any financial ties they might have with the pharmaceutical companies that make these drugs. Such ties could lead to a higher use of the drugs and a higher cost to the Medicaid program without benefiting patients.

Colorado Medicaid Doctor Prescribes a Whopping $1.1 Million of Antipsychotic Drugs in Just 2008 and 2009 Alone

Colorado’s top Medicaid prescriber of drugs at the center of a U.S. senator’s probe into fraud, waste and abuse in the Medicaid system billed nearly $1.1 million in 2008 and 2009 for 1,304 prescriptions written on four expensive antipsychotic drugs, according to data obtained by the Citizens Commission on Human Rights of Colorado.

The high-prescribing doctor was identified only by the prescriber identifier number 1093800559 in data compiled by the Colorado Department of Health Care Policy & Financing (CDHCPF) in response to a request from U.S. Senator Charles Grassley of Iowa, ranking Republican on the Senate Finance Committee, which oversees Medicaid and Medicare.

In April the senator requested 2008 and 2009 data from all 50 state Medicaid agencies on the top 10 Medicaid prescribers for each of six antipsychotic and two narcotic drugs, citing his concern they are being overprescribed at great cost to the publicly-funded Medicaid and Medicare programs. Following his review of the data, Grassley called for a federal investigation.

Collectively Colorado’s top 10 Medicaid prescribers of the six antipsychotic drugs in question billed Medicaid a total of $8,172,649 over the two-year period, billing $3,045,015 in 2008 and $5,127,634 in 2009 for a 68 percent increase.

Colorado taxpayers have good reason to be concerned not only about the mushrooming cost of expensive antipsychotic drugs prescribed by Medicaid psychiatrists, but also the medical costs of the physical damage these drugs can cause to the Medicaid patients taking them.

The ages of the patients for whom the prescriptions were written were not part of the released data, so it is not known whether the huge jump in prescriptions in Colorado reflects the growing nationwide trend of putting children on antipsychotics, especially poor children. A Rutgers University study last year found that children from low-income families, like those on Medicaid, were four times as likely as the privately insured to be put on antipsychotic drugs.

Drug studies of newer antipsychotics have found they can cause serious side effects in children, including diabetes, obesity, elevated cholesterol, seizures and strokes.

According to a recent article in The New York Times, “a marketing juggernaut…has made antipsychotics the nation’s top-selling class of drugs by revenue, $14.6 billion last year, with prominent promotions aimed at children.”

Because none of Colorado’s top Medicaid antipsychotic prescribers is identified by name in the CDHCPF data, it is not possible to track any financial ties they might have with the pharmaceutical companies that make these drugs, which could lead to a higher use of the drugs and a higher cost to the Medicaid program without benefiting patients.

Recently enacted national health care reform will require pharmaceutical companies to disclose payments to doctors beginning in 2013. In the meantime Eli Lilly & Co. and Pfizer, makers of two of the antipsychotic drugs targeted by Sen. Grassley, must already disclose their payments to doctors as part of agreements reached with the U.S. Department of Justice.

With Colorado already facing what the governor’s office estimates as a $262 million general-fund shortfall for the current 2010-11 budget and facing another $1 billion shortfall in the 2011-12 budget year, details of the number and cost of prescriptions for antipsychotic and other psychiatric in the publicly-funded Medicaid program over the past 10 years should be made public, with a special focus on the increase in the number and cost of prescriptions written on antipsychotics for children.

If you or someone you know has been harmed by taking antipsychotic drugs and you want to talk about it, we want to talk to you. Email us or call 303-789-5225. All inquiries and communication will be handled in strictest confidence. We will take action.

There is NO Suicide Epidemic in Colorado

Data being misused to alarm the public is consistent with marketing programs of the psychiatric-pharmaceutical industry

Data recently released by the Colorado Department of Public Health and Environment show that the trend in suicides in the state in effect has been statistically flat for at least 22 years. There are wide fluctuations from year to year in the rate of suicides per 100,000 population, but all within a long-term, essentially unchanged trend, as the chart below of the data illustrates. There isno suicide epidemic in Colorado.

Particularly false is the claim of a supposed epidemic of suicides among young people. The fact is that suicide is very rare among children. While the death of any child is tragic, statewide there were just 11 suicides last year in an estimated population of 1,040,402 children through age 14, for a rate of 1.1 suicide per 100,000 in 2009 – almost exactly the same rate as the 20-year average rate for this age group of 1.0. The facts show there is no suicide epidemic among younger children.

Concerning teenage suicides, the statistic currently making headlines is that suicide is the second-leading cause of death among teenagers in Colorado. But this is only because there are very few teenage deaths for any reason. While the death of any child is tragic, the fact is that there were 49 suicides last year in an estimated population of 362,423 teens ages 15 through 19 statewide, for a rate of 13.5 suicides per 100,000 population in 2009 – almost exactly the same rate as the 20-year average rate for this age group of 13.1. The facts show that suicides are not spreading more rapidly or extensively among teenagers. There is no suicide epidemic.

At a minimum, these statistics stand as testament to the monumental failure of psychiatry to lower the suicide rate after decades of prescribing antidepressants in Colorado – to the point that antidepressant residues are measurable in our waterways.

More alarming is the fact that psychiatric drugging is leading to suicides. An estimated 50% of all Americans who commit suicide are on psychiatric drugs.

Antidepressants are known to cause worsening depression, birth defects, sexual dysfunction, anxiety, panic attacks, hostility, aggression, psychosis, violence, suicide and many, many other adverse events. Long-term antidepressant users frequently report that their emotions have been deadened so much that they feel like zombies.

The dangers of antidepressants have led the FDA and regulatory authorities around the word to issue warnings concerning their use, including the FDA’s most severe, “black box” warning.

International warnings & studies on psychiatric drugs can be found through the Citizens Commission on Human Rights International’s psychiatric drug search engine.

Adverse psychiatric drug reactions reported to the U.S. Food and Drug Administration’s Medwatch can be searched here.

Despite the fact that the suicide rate for teenagers in Colorado has been essentially unchanged for at least 20 years, “suicide as the second-leading cause of death among teenagers” is being used to gain sympathy and support from the public, school administrators, physicians, public officials, and state legislators for requiring children to be screened for depression in the name of suicide prevention.

The screening surveys used, however, consider the normal variations in human behavior as symptoms of mental illness. In particular, teenagers, with their wide range of behavior, are found to have “mental disorders” in high numbers. This is because screening that targets teenagers, such as TeenScreen, asks questions that could be answered “Yes” by almost any normal teenager, such as:

Has there been a time when nothing was fun for you and you just weren’t interested in anything?
Has there been a time when you felt you couldn’t do anything well or that you weren’t as good-looking or as smart as other people?
How often did your parents get annoyed or upset with you because of the way you were feeling or acting?
Have you often felt very nervous when you’ve had to do things in front of people?
Have you often worried a lot before you were going to play a sport or game or do some other activity?

A pilot program using TeenScreen should serve as a chilling warning to Coloradoans about what it means when teenagers are screened for depression. During 2001-03, TeenScreen was used on teenagers at a Denver public high school and a Denver homeless shelter. The results, unabashedly published at the time on the website of the Mental Health Association of Colorado (now Mental Health America of Colorado), are shocking to anyone – except apparently those with ties in with the psychiatric industry:

Half (50%) of the screened high school students were found to be at risk of suicide!
Nearly three out of four youths (71%) screened at the homeless shelter were found to have psychiatric disorders!

Clearly these screening surveys are identifying all sorts of young people as “mentally ill” when they are not. Even the developer of the TeenScreen survey, psychiatrist David Shaffer, who has been the recipient of huge dollars from pharmaceutical companies (see “TeenScreen, A Front Group for the Psycho-Pharmaceutical Industrial Complex”), himself admits that TeenScreen “does identify a whole bunch of kids who aren’t really suicidal, so you get a lot of false-positives. And that means if you’re running a large program at a school, you’re going to cripple the program because you’re going to have too many kids you have to do something about.”

And what happens when the screening identifies so many children “you have to do something about?” It means a bonanza for the pharmaceutical companies and the psychiatrists who make a living from psychiatric drugging. Young people with their wide range of childhood behavior, or with behavioral symptoms caused by any number of underlying, often undiagnosed physicalillnesses or abnormalities, will be labeled with “mental disorders” that follow them through life.

They will likely get referred to a psychiatrist, who will in all probability prescribe powerful, mind-altering psychiatric drugs, with their long lists of harmful and even life-threatening side effects. The results of a survey published several years ago in the Journal of the American Academy of Child and Adolescent Psychiatry revealed that 9 out of 10 children who see a psychiatrist will be prescribed psychiatric drugs.

The facts show that there is no epidemic of suicides in Colorado. So who is behind the hysteria being whipped up in the state over suicides? Pharmaceutical companies have three steps in their marketing programs, the first of which is to elevate the importance of a condition, making it appear far more serious & widespread than previously thought. This first step is well underway in Colorado, forwarded by psychiatrists and psychiatric-industry front groups like the National Alliance on Mental Illness (NAMI), using disinformation about a nonexistent “epidemic of suicides” supposedly sweeping the state.

The story of the unholy alliance between psychiatry and the drug companies, with the slick marketing schemes and scientific deceit that have created an $80 billion profit center, has been documented in “The Marketing of Madness: Are We All Insane?”, a multi-award-winning documentary film produced by CCHR International. To order your free copy of the DVD, click here.

If you, a loved one, or someone you know has been harmed by a psychiatrist or other mental-health worker and you want to talk about it, we want to talk to you. Email us or call 303-789-5225. All inquiries and communication will be handled in strictest confidence. We will take action.

Diet is Strongly Associated with the Risk of Depression

A team of researchers from England and France found that dietary patterns over a five-year period had a significant effect on the risk of feeling depressed. People eating a predominantly natural-foods diet of mostly vegetables, fruits, fish, and whole grains were one-fourth less likely to have depression. Those eating mainly processed foods, including processed meats, refined grains, fried foods, high-fat dairy products, and sweetened desserts were more than 50 percent more likely to feel depressed. The natural-foods diet is richer in vitamins, minerals, and good fats that help maintain healthy moods. (Akbaraly TN, Brunner EJ, Ferrie JE, et al. Dietary pattern and depressive symptoms in middle age. British Journal of Psychiatry, 2009;195:408-413)

Increased Blood Clot Risk with Antipsychotic Drugs

Scientists in the UK believe that antipsychotic drugs raise the risks of dangerous blood clots

This risk had already been spotted by some scientists and seems now to be confirmed by a new study. Almost 16,000 people suffered a deep vein thrombosis (formation of a blood clot in a deep vein) and 9,000 people suffered a clot in the lung.

Study subjects taking newer “atypical” antipsychotics had a 73% higher chance of developing a clot, reports BBC News.

Other studies have already revealed a higher stroke risk among patients taking antipsychotics.

For more information on psychiatric drugs, visit CCHR’s Psychiatric Drug Side Effects search engine.

Antidepressants Have Been Found Contaminating Fish in Boulder

Scientists from the U.S. Geological Survey and the University of Colorado have found antidepressants, like Prozac, accumulating in the brains of fish near Boulder’s wastewater treatment plant, causing the reactions of the fish and their response to predators to slow down, according to the Denver Post: http://www.denverpost.com/ci_16037537.

Fish act as an early warning system for the presence of contaminants in water supplies. Studies have already documented the disruption to the reproductive systems of fish from contaminants finding their way into Colorado waterways.

In a recent article in The Durango Herald about personal care and pharmaceutical products in our water, Mike Meschke, environmental health director for the San Juan Basin Health Department, says, “Many of these compounds are not biodegradable and persist in our rivers and streams because they pass through treatment plants.” The chemicals may produce adverse developmental, reproductive, neurological and immune effects in humans and wildlife. “We’re rolling the dice,” according to Meschke, “We’re playing with an environmental cocktail in our water.”http://www.durangoherald.com/sections/Features/.

With concern growing over the potential danger to humans, wildlife and the environment, Colorado and federal authorities have ramped up efforts to test state rivers and reservoirs.

Man Died in Restraints at Colorado State Psychiatric Hospital

CMHIP withholds data requested by the district attorney and county coroner

An obese man who died in the custody of the Colorado Mental Health Institute at Pueblo (CMHIP) suffocated while being restrained face down on a table. He may have been hog-tied.

Troy Allen Geske, 41, died August 10 at the psychiatric institution. An affidavit for a search warrant says that Geske died after he was put in four-point restraint, in which the feet are attached to the hands behind the back.

A spokeswoman for the Colorado Department of Human Services, which oversees the psychiatric facility, denied Geske was in four-point restraint. But Pueblo County District Attorney Bill Thiebaut said the information in the affidavit is corroborated by evidence that has been collected, including video of Geske in restraints, according to the Pueblo Chieftain:
http://chieftain.com/news/local/article_f75a23c2-b72f-11df-9494-001cc4c002e0.html
http://chieftain.com/news/local/article_59e5ca9c-b653-11df-8d64-001cc4c002e0.html

At 5-feet-8 and 265 pounds, Geske was at greater risk of “positional asphyxiation” when he was restrained on his stomach with his own weight pressing down on his lungs and diaphragm. Federal law requires constant, close monitoring of anyone face down in restraints to prevent suffocation.

The results of an autopsy and toxicology tests have not yet been released.

After Geske’s death, hospital police could have called in the 10th Judicial District’s critical incident team (CIT) for an independent investigation of the incident by a team of investigators from outside law enforcement agencies, but did not do so, according to the Pueblo Chieftain: http://chieftain.com/news/local/article_b4e5d92e-b7f1-11df-abf2-001cc4c002e0.html

The CIT investigates serious incidents involving police officers under an agreement to which CMHIP is a party. Hospital police were reportedly present when staff attempted to revive Geske.

CMHIP has also refused to turn over certain information requested by investigators. District Attorney Thiebaut says he will go to court if necessary to get information he believes his office is entitled to, according to the Chieftain.

For more than 40 years, the Citizens Commission on Human Rights has advocated against any form of psychiatric treatment that is torturous, cruel, inhuman or degrading, as laid out in its Mental Health Declaration of Human Rights.